Ulipristal Acetate Gedeon Richter

RSS

Withdrawn

This medicine's authorisation has been withdrawn

ulipristal acetate
MedicineHumanWithdrawn

Icelandic is available via eTranslation, the European Commission's machine translation service.

Translate to Icelandic | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 14 June 2021, the European Commission withdrew the marketing authorisation for Ulipristal Acetate Gedeon Richter (ulipristal acetate) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Gedeon Richter Plc., which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Ulipristal Acetate Gedeon Richter was granted marketing authorisation in the EU on 27 August 2018 for the treatment of uterine fibroids. The marketing authorisation was initially valid for a 5-year period. 

Ulipristal Acetate Gedeon Richter was a duplicate application to Esmya, which is marketed in several EU countries. 

The European Public Assessment Report (EPAR) for Ulipristal Acetate Gedeon Richter is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (805.8 KB - PDF)

Skoða

español (ES) (708.53 KB - PDF)

Skoða

čeština (CS) (781.02 KB - PDF)

Skoða

dansk (DA) (705.89 KB - PDF)

Skoða

Deutsch (DE) (711.46 KB - PDF)

Skoða

eesti (ET) (694.54 KB - PDF)

Skoða

ελληνικά (EL) (805.14 KB - PDF)

Skoða

français (FR) (710.29 KB - PDF)

Skoða

hrvatski (HR) (734.95 KB - PDF)

Skoða

italiano (IT) (706 KB - PDF)

Skoða

latviešu (LV) (156.85 KB - PDF)

Skoða

lietuvių (LT) (733.64 KB - PDF)

Skoða

magyar (HU) (779.92 KB - PDF)

Skoða

Malti (MT) (793.31 KB - PDF)

Skoða

Nederlands (NL) (707.03 KB - PDF)

Skoða

polski (PL) (781.89 KB - PDF)

Skoða

português (PT) (698.7 KB - PDF)

Skoða

română (RO) (734.45 KB - PDF)

Skoða

slovenčina (SK) (784.27 KB - PDF)

Skoða

slovenščina (SL) (779.14 KB - PDF)

Skoða

suomi (FI) (705.48 KB - PDF)

Skoða

svenska (SV) (706.53 KB - PDF)

Skoða

български (BG) (805.8 KB - PDF)

Skoða

español (ES) (708.53 KB - PDF)

Skoða

čeština (CS) (781.02 KB - PDF)

Skoða

dansk (DA) (705.89 KB - PDF)

Skoða

Deutsch (DE) (711.46 KB - PDF)

Skoða

eesti (ET) (694.54 KB - PDF)

Skoða

ελληνικά (EL) (805.14 KB - PDF)

Skoða

français (FR) (710.29 KB - PDF)

Skoða

hrvatski (HR) (734.95 KB - PDF)

Skoða

italiano (IT) (706 KB - PDF)

Skoða

latviešu (LV) (156.85 KB - PDF)

Skoða

lietuvių (LT) (733.64 KB - PDF)

Skoða

magyar (HU) (779.92 KB - PDF)

Skoða

Malti (MT) (793.31 KB - PDF)

Skoða

Nederlands (NL) (707.03 KB - PDF)

Skoða

polski (PL) (781.89 KB - PDF)

Skoða

português (PT) (698.7 KB - PDF)

Skoða

română (RO) (734.45 KB - PDF)

Skoða

slovenčina (SK) (784.27 KB - PDF)

Skoða

slovenščina (SL) (779.14 KB - PDF)

Skoða

suomi (FI) (705.48 KB - PDF)

Skoða

svenska (SV) (706.53 KB - PDF)

Skoða

Product information

български (BG) (1.87 MB - PDF)

Skoða

español (ES) (1006.84 KB - PDF)

Skoða

čeština (CS) (980.38 KB - PDF)

Skoða

dansk (DA) (985.58 KB - PDF)

Skoða

Deutsch (DE) (1.04 MB - PDF)

Skoða

eesti (ET) (931.37 KB - PDF)

Skoða

ελληνικά (EL) (1.98 MB - PDF)

Skoða

français (FR) (1018.25 KB - PDF)

Skoða

hrvatski (HR) (1.07 MB - PDF)

Skoða

italiano (IT) (974.64 KB - PDF)

Skoða

latviešu (LV) (1.8 MB - PDF)

Skoða

lietuvių (LT) (1.8 MB - PDF)

Skoða

magyar (HU) (1.56 MB - PDF)

Skoða

Malti (MT) (1.62 MB - PDF)

Skoða

Nederlands (NL) (967.06 KB - PDF)

Skoða

polski (PL) (1.59 MB - PDF)

Skoða

português (PT) (987.36 KB - PDF)

Skoða

română (RO) (1.09 MB - PDF)

Skoða

slovenčina (SK) (1.55 MB - PDF)

Skoða

slovenščina (SL) (1.5 MB - PDF)

Skoða

suomi (FI) (1013.08 KB - PDF)

Skoða

svenska (SV) (948.19 KB - PDF)

Skoða

Íslenska (IS) (975.68 KB - PDF)

Skoða

norsk (NO) (973.21 KB - PDF)

Skoða
14/06/2021
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (640.72 KB - PDF)

Skoða

español (ES) (597.33 KB - PDF)

Skoða

čeština (CS) (622.2 KB - PDF)

Skoða

dansk (DA) (596.79 KB - PDF)

Skoða

Deutsch (DE) (597.21 KB - PDF)

Skoða

eesti (ET) (597 KB - PDF)

Skoða

ελληνικά (EL) (640.57 KB - PDF)

Skoða

français (FR) (597.63 KB - PDF)

Skoða

hrvatski (HR) (606.66 KB - PDF)

Skoða

italiano (IT) (596.99 KB - PDF)

Skoða

latviešu (LV) (634.12 KB - PDF)

Skoða

lietuvių (LT) (617.71 KB - PDF)

Skoða

magyar (HU) (629.46 KB - PDF)

Skoða

Malti (MT) (630.46 KB - PDF)

Skoða

Nederlands (NL) (597.66 KB - PDF)

Skoða

polski (PL) (622.63 KB - PDF)

Skoða

português (PT) (597.51 KB - PDF)

Skoða

română (RO) (616.82 KB - PDF)

Skoða

slovenčina (SK) (622.69 KB - PDF)

Skoða

slovenščina (SL) (621.01 KB - PDF)

Skoða

suomi (FI) (597.62 KB - PDF)

Skoða

svenska (SV) (590.12 KB - PDF)

Skoða

Íslenska (IS) (597.28 KB - PDF)

Skoða

norsk (NO) (597.55 KB - PDF)

Skoða

Product details

Name of medicine
Ulipristal Acetate Gedeon Richter
Active substance
ulipristal acetate
International non-proprietary name (INN) or common name
ulipristal acetate
Therapeutic area (MeSH)
Leiomyoma
Anatomical therapeutic chemical (ATC) code
G03XB02

Pharmacotherapeutic group

Sex hormones and modulators of the genital system

Therapeutic indication

Ulipristal acetate is indicated for one treatment course of pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age who are not eligible for surgery.

Authorisation details

EMA product number
EMEA/H/C/005017
Marketing authorisation holder
Gedeon Richter Plc.

Gyomroi ut 19-21
1103 Budapest
Hungary

Opinion adopted
28/06/2018
Marketing authorisation issued
27/08/2018
Revision
1

Assessment history

български (BG) (1.16 MB - PDF)

Skoða

español (ES) (717.52 KB - PDF)

Skoða

čeština (CS) (1.08 MB - PDF)

Skoða

dansk (DA) (776.12 KB - PDF)

Skoða

Deutsch (DE) (809.32 KB - PDF)

Skoða

eesti (ET) (780.64 KB - PDF)

Skoða

ελληνικά (EL) (1.12 MB - PDF)

Skoða

français (FR) (724.64 KB - PDF)

Skoða

hrvatski (HR) (851.47 KB - PDF)

Skoða

italiano (IT) (1.33 MB - PDF)

Skoða

latviešu (LV) (1.01 MB - PDF)

Skoða

lietuvių (LT) (869.2 KB - PDF)

Skoða

magyar (HU) (988.65 KB - PDF)

Skoða

Malti (MT) (1.05 MB - PDF)

Skoða

Nederlands (NL) (710.99 KB - PDF)

Skoða

polski (PL) (1.01 MB - PDF)

Skoða

português (PT) (719.58 KB - PDF)

Skoða

română (RO) (879.76 KB - PDF)

Skoða

slovenčina (SK) (1013.26 KB - PDF)

Skoða

slovenščina (SL) (1001.18 KB - PDF)

Skoða

suomi (FI) (704.64 KB - PDF)

Skoða

svenska (SV) (709.6 KB - PDF)

Skoða

Íslenska (IS) (708.37 KB - PDF)

Skoða

norsk (NO) (699.99 KB - PDF)

Skoða

This page was last updated on

Share this page